|
|
|
Volumn 22, Issue 135, 2013, Pages 40-
|
|
Saxagliptin + metformin. Mostly disadvantages.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADAMANTANE;
ANTIDIABETIC AGENT;
BIOLOGICAL MARKER;
DIPEPTIDE;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
DRUG DERIVATIVE;
GLYCOSYLATED HEMOGLOBIN;
HEMOGLOBIN A1C PROTEIN, HUMAN;
METFORMIN;
SAXAGLIPTIN;
ARTICLE;
BLOOD;
DRUG COMBINATION;
HUMAN;
METABOLISM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
ORAL DRUG ADMINISTRATION;
TABLET;
TREATMENT OUTCOME;
ADAMANTANE;
ADMINISTRATION, ORAL;
BIOLOGICAL MARKERS;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDES;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
DRUG COMBINATIONS;
HEMOGLOBIN A, GLYCOSYLATED;
HUMANS;
HYPOGLYCEMIC AGENTS;
METFORMIN;
TABLETS;
TREATMENT OUTCOME;
|
|
EID: 84874964186
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|